About this trial
This prospective cohort study aims to evaluate median nerve cross-sectional area and intraneural vascularity using power Doppler ultrasonography in patients with carpal tunnel syndrome. Ultrasonographic findings will be compared between diabetic and non-diabetic patients. Clinical severity and electrophysiological findings will be correlated with ultrasonographic parameters.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
clinically and electrophysiologically confirmed carpal tunnel syndrome
symptom duration > 3 months
written informed consent
Disqualifiers
previous wrist surgery
cervical radiculopathy
inflammatory arthritis
pregnancy
Trial population
Carpal Tunnel Syndrome Patients
Trial design
Cohort
Prospective
Treatments tested in this trial
Doppler ultrasound
Diagnostic testThe predictive power of cross-sectional area and intraneural blood flow measured by ultrasound on surgical outcomes will be tested.
Treatment groups
Trial outcomes
Primary outcomes
Intraneural Vascularity
Intraneural blood flow will be evaluated using power Doppler ultrasonography at the level of the carpal tunnel inlet. The presence and degree of intraneural vascularity will be graded using a semi-quantitative scoring system: 0 = No detectable intraneural flow 1. = Single vessel signal 2. = Multiple vessel signals 3. = Marked hypervascularity The total score ranges from 0 to 3. Higher scores indicate increased intraneural vascularity.
Cross sectional Area
The cross-sectional area of the median nerve will be measured using ultrasonography at the level of the pisiform bone (carpal tunnel inlet) and proximal to transvers carpal ligament. Measurements will be obtained by tracing the inner border of the hyperechoic epineurium. Values will be recorded in square millimeters (mm²). Higher values indicate greater nerve swelling.
Secondary outcomes
Boston Carpal Tunnel Questionnaire
Change in Symptom Severity Score of the Boston Carpal Tunnel Questionnaire The Boston Carpal Tunnel Questionnaire is a patient-reported outcome measure consisting of 11 questions assessing symptom severity. Each item is scored from 1 (no symptoms) to 5 (most severe symptoms). The total score ranges from 11 to 55. Higher scores indicate worse symptom severity.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: